Coeptis Therapeutics Files 8-K
Ticker: COEPW · Form: 8-K · Filed: Jan 22, 2025 · CIK: 1759186
Sentiment: neutral
Topics: 8-K, financial-reporting
Related Tickers: COEP
TL;DR
COEP filed an 8-K on Jan 21, 2025 - standard disclosure, no major news yet.
AI Summary
On January 21, 2025, Coeptis Therapeutics Holdings, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure of material information. No specific financial figures or significant events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing serves as a public record of important corporate events or financial updates for Coeptis Therapeutics Holdings, Inc., allowing investors and the public to stay informed.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate or significant risks.
Key Players & Entities
- Coeptis Therapeutics Holdings, Inc. (company) — Registrant
- January 21, 2025 (date) — Date of Earliest Event Reported
- 105 Bradford Rd , Suite 420 Wexford , Pennsylvania 15 (location) — Business Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of January 21, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 21, 2025.
What is the company's full legal name as stated in the filing?
The company's full legal name is Coeptis Therapeutics Holdings, Inc.
What is the state of incorporation for Coeptis Therapeutics Holdings, Inc.?
The state of incorporation is Delaware.
What is the business address provided for Coeptis Therapeutics Holdings, Inc.?
The business address provided is 105 Bradford Rd, Suite 420, Wexford, Pennsylvania, 15090.
Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-01-22 16:45:32
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Mark
- $11.50 — e-half of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capita
- $1.00 — id price for its common stock was below $1.00 per share for 30 consecutive business d
- $1.00 b — ompany has regained compliance with the $1.00 bid price requirement for continued listi
Filing Documents
- coeptis_8k.htm (8-K) — 32KB
- coeptis_ex9901.htm (EX-99.1) — 8KB
- 0001683168-25-000482.txt ( ) — 261KB
- coep-20250121.xsd (EX-101.SCH) — 3KB
- coep-20250121_def.xml (EX-101.DEF) — 29KB
- coep-20250121_lab.xml (EX-101.LAB) — 36KB
- coep-20250121_pre.xml (EX-101.PRE) — 26KB
- coeptis_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events As previously reported by Coeptis Therapeutics Holdings, Inc. (the "Company"), it had received a written notice from The Nasdaq Stock Market ("Nasdaq"), indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) as the Company's closing bid price for its common stock was below $1.00 per share for 30 consecutive business days. On January 21, 2025, the Company was notified by The Nasdaq Stock Market that the Company has regained compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the matter is now closed. On January 22, 2025, the Company issued a press release announcing the determination of continued listing on the Nasdaq Capital Market. A copy of the press release is included with this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No . Description 99.1 Press Release, dated January 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: January 22, 2025 By: /s/ David Mehalick David Mehalick Chief Executive Officer 3